Calculus Capital has taken part in a £7.25m investment in UK molecular diagnostics firm Premaitha Health, which has listed on the AIM of the London Stock Exchange.
Nutrisens management team, led by CEO Georges Devesa, retains a significant stake in the company
Intention to list comes four years after the GP acquired the company via its fourth fund
Online optician has previously received VC funding from investors including Grazia Equity and Goldman Sachs
Platform will enable smaller investors to put their secondaries stakes up for sale